ACRS — Aclaris Therapeutics Share News
0.000.00%
Last trade - 00:00- $532.87m
- $441.32m
- $7.83m
Brief: Aclaris Therapeutics Q2 Net Income USD -15.429 Million Vs. IBES Estimate USD -16.4 Million
Aclaris Therapeutics Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Positive Top-Line Results From Open-Label Phase 2A Trial Of Ati-2138, A Potent And Selective Investigational Inhibitor Of Itk And Jak3 Trial Achieves Primary And Key Secondary Endpoints
Brief: Aclaris Therapeutics Announces Leadership Transition
Brief: Aclaris Therapeutics Initiates Phase 1A/1B Program For Its Novel Bispecific Antibody Ati-052
Brief: Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug In Atopic Dermatitis
Aclaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Aclaris Therapeutics Q1 Net Income USD -15.085 Million Vs. IBES Estimate USD -13.3 Million
Aclaris Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer
Brief: Aclaris Therapeutics Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Aclaris Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Aclaris Therapeutics Q4 Revenue USD 9.211 Million Vs. IBES Estimate USD 2.11 Million
Aclaris Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Brief: Aclaris Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Walmart, Fiserv, Rumble
U.S. STOCKS ON THE MOVE-Nordstrom, Optical Cable, Lexicon
U.S. STOCKS ON THE MOVE-Eli Lilly, Playa Hotels, Rumble
Aclaris Therapeutics gains after H.C. Wainwright upgrades to 'buy'